Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706038 | 0.83 | ESR1 (0.32) | ESR1ESR2HPGD | |
| SCHEMBL190639 | 0.81 | ESR1 (0.44) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL704609 | 0.81 | ESR1 (0.44) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL18108503 | 0.78 | ESR1 (0.38) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL18108340 | 0.77 | ESR1 (0.41) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL18108302 | 0.77 | ESR1 (0.41) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL707750 | 0.75 | ESR1 (0.44) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL63526 | 0.73 | ESR1 (0.70) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL439492 | 0.73 | ESR1 (0.48) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL239179 | 0.73 | ESR1 (0.48) | ESR1ESR2MAPTNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092264-A1 | METHOD FOR CAPPING MQ-TYPE SILICONE RESINS | Dow Corning Corporation (US) | 2016-11-16 | — | — | EP | claimed |
| US-20160326320-A1 | Method For Capping Mq-Type Silicone Resins | DOW COMING CORPORATION (US) | 2016-11-10 | — | — | US | claimed |
| WO-2015105931-A1 | METHOD FOR CAPPING MQ-TYPE SILICONE RESINS | DOW CORNING CORPORATION (US) | 2015-07-16 | — | — | WO | claimed |
| EP-4737444-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | Gilead Sciences, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250179004-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-114787139-B | Methods and intermediates for preparing MCL1 inhibitors | 吉利德科学公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12202782-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4484435-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4065567-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES INC (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024081372-A1 | PROCESSES FOR THE PREPARATION OF THE AGENT-LINKER CONJUGATE CL2A-SN-38 AND THE IMMUNOCONJUGATES SACITUZUMAB GOVITECAN AND LABETUZUMAB GOVETICAN | GILEAD SCIENCES, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-4182709-A | Manufacture of semi-synthetic penicillin antibiotics | GLAXO GROUP LIMITED (GB) | 1980-01-08 | — | — | US | disclosed |
| US-4160863-A | ANTIBIOTIC | BRISTOL-MYERS COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4113591-A | BROMINATION IN PRESENCE OF ULTRAVIOLET RADIATION, VISIBLE LIGHT, OR GAMMA RAYS | GLAXO LABORATORIES LIMITED (GB) | 1978-09-12 | — | — | US | disclosed |
| US-4066657-A | ANTIBACTERIAL AGENTS FOR ANIMAL FEED SUPPLEMENTS | PFIZER INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4036846-A | ANTIBACTERIAL | PFIZER INC. (US) | 1977-07-19 | — | — | US | disclosed |
| US-4031077-A | Antibacterial 3-phosphono penams | PFIZER INC. (US) | 1977-06-21 | — | — | US | disclosed |
| US-3994939-A | BACTERICIDES | PFIZER INC. (US) | 1976-11-30 | — | — | US | disclosed |
| US-3943123-A | ANTIBIOTIC | KONINKLIJKE NEDERLANDSCHE GIST-EN SPIRITUSFABRIEK N.V. (NL) | 1976-03-09 | — | — | US | disclosed |
| US-3935342-A | POLYMERIZATION WITH AN UNSATURATED SILYL MONOMER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | ESR1 4558/4885ESR2 4681/4885MAPT 3023/4885 |
| US-12202782-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BCL3, XIAP | ESR1 4273/4885ESR2 4077/4885MAPT 3861/4885 |
| US-20250179004-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BCL3, XIAP | ESR1 4273/4885ESR2 4077/4885MAPT 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.